Obrixtamig Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Obrixtamig comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Small Cell Lung Carcinoma. Most recent publication: Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas., Future Oncol, 2022.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.Wermke M, Felip E, Gambardella V, et al. · Future Oncol · 2022
Publications by year
2022–2022: 1 publications.
2022
1
Publications by indication
Small Cell Lung Carcinoma (1)
- Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Publications by journal
- Future Oncol1 paper
All Obrixtamig publications (1)
2022 (1 paper)
- Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.Wermke M, Felip E, Gambardella V, et al. · Future Oncol · 2022 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Thu, 14 May 2026 22:17:23 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).